Table 1.
Demographics and clinical characteristics at baseline of the parent study for patients who entered the OLTPa.
| All patients (n = 383) | |
|---|---|
| Age, mean years (SD) | 41.3 (10.9) |
| Sex, n female (%) | 303 (79) |
| Race, n white (%) | 354 (92) |
| Age at migraine onset, mean years (SD) | 20.9 (11.3) |
| Duration of disease, mean years (SD) | 20.9 (11.9) |
| History of migraine with aura, n (%) | 137 (36) |
| Monthly migraine days, mean (SD) | 8.7 (2.7) |
| Monthly headache days, mean (SD) | 9.8 (2.7) |
| Monthly migraine-specific medication daysb, mean (SD) | 4.3 (3.7) |
| Prior prophylactic history, n (%) | |
| Naïve | 214 (56) |
| Prior use | 169 (44) |
| Treatment failurec | 138 (36) |
| Other | 31 (8) |
a
Baseline was prior to the parent study double-blind phase.
b
Migraine-specific medications were triptans and ergot amine-derivative. Two hundred and fifty-nine patients (68%) received triptans and four (1%) patients received ergotamine derivatives during the baseline period.
c
Treatment failure included discontinuation due to lack of efficacy and/or side effects.
Q1, first quartile; Q3, third quartile; SD, standard deviation.